Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 57.21% is in line with its 5-year average of 59.96%, near the low end of its 5-year range (56.27%–64.33%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.17% below its 12-month average of 57.31%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 57.19%.
GROSS MARGIN
57.21%
GROSS MARGIN AVG TTM
57.31%
GROSS MARGIN AVG 3Y
58.91%
GROSS MARGIN AVG 5Y
59.96%
GROSS MARGIN AVG 10Y
64.48%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.17%
CURRENT VS 3Y AVG
-2.88%
CURRENT VS 5Y AVG
-4.58%
CURRENT VS 10Y AVG
-11.27%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+38.26%
vs the sector median at left
Viemed Healthcare, Inc.
Market Cap
$355.36M
Gross Margin
57.21%
TTM Avg
57.31%
3Y Avg
58.91%
5Y Avg
59.96%
Market Cap
$354.48M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$354.90M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
Market Cap
$357.39M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$359.88M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$361.82M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$348.51M
Gross Margin
99.32%
TTM Avg
95.85%
3Y Avg
93.96%
5Y Avg
99.79%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viemed Healthcare, Inc. (VMD) | $355.36M | 57.21% | 57.31% | 58.91% | 59.96% |
| Turn Therapeutics Inc. (TTRX)vs › | $354.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $354.90M | 98.15% | 96.49% | 98.25% | 98.83% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $357.39M | 0.00% | 50.00% | 75.00% | 66.67% |
| Ocugen, Inc. (OCGN)vs › | $352.91M | 45.86% | 48.66% | 71.42% | -2398.51% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.88M | 93.73% | 92.44% | 93.34% | 78.89% |
| Embecta Corp. (EMBC)vs › | $349.87M | 59.89% | 63.90% | 65.83% | 67.05% |
| Opus Genetics, Inc. (IRD)vs › | $361.82M | 99.87% | 100.00% | 100.00% | 83.33% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $348.51M | 99.32% | 95.85% | 93.96% | 99.79% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.02M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
57.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 57.19% |
| 2026-03-31 | 56.27% |
| 2025-12-31 | 57.89% |
| 2025-09-30 | 57.49% |
| 2025-06-30 | 57.69% |
| 2025-03-31 | 56.28% |
| 2024-12-31 | 59.54% |
| 2024-09-30 | 59.26% |
| 2024-06-30 | 59.84% |
| 2024-03-31 | 58.91% |
| 2023-12-31 | 63.29% |
| 2023-09-30 | 61.86% |
| 2023-06-30 | 60.28% |
| 2023-03-31 | 60.68% |
| 2022-12-31 | 61.04% |
| 2022-09-30 | 60.55% |
| 2022-06-30 | 61.21% |
| 2022-03-31 | 61.21% |
| 2021-12-31 | 61.52% |
| 2021-09-30 | 62.77% |
| 2021-06-30 | 64.33% |
| 2021-03-31 | 62.44% |
| 2020-12-31 | 61.46% |
| 2020-09-30 | 58.16% |
| 2020-06-30 | 60.50% |
| 2020-03-31 | 65.33% |
| 2019-12-31 | 47.57% |
| 2019-09-30 | 68.98% |
| 2019-06-30 | 72.02% |
| 2019-03-31 | 72.17% |
| 2018-12-31 | 73.80% |
| 2018-09-30 | 76.11% |
| 2018-06-30 | 73.01% |
| 2018-03-31 | 74.78% |
| 2017-12-31 | 75.18% |
| 2017-09-30 | 74.78% |
| 2017-06-30 | 72.09% |
| 2017-03-31 | 72.39% |
| 2016-12-31 | 84.00% |
| 2016-09-30 | 75.21% |
